ArticleHuman cell2007
Establishment of a new cell line of endometrioid carcinoma of the ovary and its chemosensitivity.
Article in Human cell, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Article
- Chondroitin Sulfate Proteoglycan 4 Provides New Treatment Approach to Preventing Peritoneal Dissemination in Ovarian Cancer.International journal of molecular sciences · 2024Article
- Microphthalmia-Associated Transcription Factor-Dependent Melanoma Cell Adhesion Molecule Activation Promotes Peritoneal Metastasis of Ovarian Cancer.International journal of molecular sciences · 2020Article
- Article
- Synchronous endometrioid endometrial and ovarian cancer in a 34-year-old woman.BMJ case reports · 2015Article
- HOXB13 and ALX4 induce SLUG expression for the promotion of EMT and cell invasion in ovarian cancer cells.Oncotarget · 2015Article
- Establishment and characterization of a cell line (NOMH-1) originating from a human endometrioid adenocarcinoma of the ovary.Journal of ovarian research · 2013Article
- The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells.Cancer science · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new cell line (NOE) of human ovarian endometrioid carcinoma was established and characterized. The cell line showed a short spindle-shaped morphology and continued to grow for more than 4 months without contact inhibition. The doubling time was approximately 15.5 h at the 10th passage. The chromosome number was aneuploid. The IC50 values of paclitaxel, cisplatin and carboplatin were 26.4 ng/mL, 2.4 microg/mL and 32.5 microg/mL, respectively. The NOE cells expressed estrogen receptor alpha. In nude mice, we confirmed tumor formation of NOE cells. These results indicated that NOE cells showed similar chemosensitivity and properties to those of the original tumor and might be useful in basic studies on the diagnosis, treatment and etiology of ovarian tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.